FOXO TECHNOLOGIES INC. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
FOXO TECHNOLOGIES INC. (FOXO) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $68.22 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2026-08-14
- FOXO TECHNOLOGIES INC. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2025-03-31 was $68.22K.
- FOXO TECHNOLOGIES INC. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2024-09-30 was $24.45K.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 3 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 3 month as first filed |
|---|---|---|
| 2025-03-31 | $68.22K 10-Q · filed 2026-08-14 | |
| 2024-09-30 | $24.45K 10-Q · filed 2025-11-10 | $24.00K 10-Q · filed 2024-11-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |